Literature DB >> 9658393

Antisense therapy of hepatitis B virus infection.

W B Offensperger1, S Offensperger, H E Blum.   

Abstract

Chronic infection with the hepatitis B virus (HBV) is a major health problem worldwide. The only established therapy is interferon-a with an efficacy of only 30-40% in highly selected patients. The discovery of animal viruses closely related to the HBV has contributed to active research on antiviral therapy of chronic hepatitis B. The animal model tested and described in this article are Peking ducks infected with the duck hepatitis B virus (DHBV). Molecular therapeutic strategies aimed at blocking gene expression include antisense DNA. An antisense oligodeoxynucleotide directed against the 5'-region of the preS gene of DHBV inhibited viral replication and gene expression in vitro in primary duck hepatocytes and in vivo in Peking ducks. These results demonstrate the potential clinical use of antisense DNA as antiviral therapeutics.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9658393     DOI: 10.1007/BF02760817

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  60 in total

1.  High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles.

Authors:  M Cotten; E Wagner; K Zatloukal; S Phillips; D T Curiel; M L Birnstiel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

Review 2.  Human gene therapy.

Authors:  W F Anderson
Journal:  Science       Date:  1992-05-08       Impact factor: 47.728

3.  Primary hepatocellular carcinoma.

Authors:  J R Wands; H E Blum
Journal:  N Engl J Med       Date:  1991-09-05       Impact factor: 91.245

4.  Intracellular distribution of microinjected antisense oligonucleotides.

Authors:  J P Leonetti; N Mechti; G Degols; C Gagnor; B Lebleu
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

5.  Antisense oligodeoxynucleotides provide insight into mechanism of translation initiation of two Sendai virus mRNAs.

Authors:  K C Gupta
Journal:  J Biol Chem       Date:  1987-06-05       Impact factor: 5.157

6.  A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells.

Authors:  A V Kabanov; S V Vinogradov; A V Ovcharenko; A V Krivonos; N S Melik-Nubarov; V I Kiselev; E S Severin
Journal:  FEBS Lett       Date:  1990-01-01       Impact factor: 4.124

Review 7.  Human gene therapy.

Authors:  R A Morgan; W F Anderson
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

8.  Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus.

Authors:  S Agrawal; J Goodchild; M P Civeira; A H Thornton; P S Sarin; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

9.  Isolation and characterization of a hepatitis B virus endemic in herons.

Authors:  R Sprengel; E F Kaleta; H Will
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

10.  Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus.

Authors:  M Matsukura; K Shinozuka; G Zon; H Mitsuya; M Reitz; J S Cohen; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

View more
  1 in total

1.  Masked antisense: a molecular configuration for discriminating similar RNA targets.

Authors:  M R Stocks; T H Rabbitts
Journal:  EMBO Rep       Date:  2000-07       Impact factor: 8.807

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.